FDA announces patient-focused drug development meeting on long Covid

In a new Federal Register notice, the FDA announced that it will convene a public meeting on April 25 to hear patient perspectives and priorities on identifying and treating long Covid. While objective measures to diagnose the condition are lacking, the agency appears to be starting with patient-focused considerations for potential treatments. Long Covid is defined as persistence of COVID-19 symptoms 4 weeks beyond SARS-CoV-2 infection, per the Federal Register meeting announcement.

Fill out the form to read the full article.

Copy link
Powered by Social Snap